MRKR: יחס מחיר לרווח לקצב צמיחה Marker Bio

Marker Therapeutics maintains a high reputation among hematologists due to its innovative MultiTAA system. The team brings together top immunologists attracted by a mission to transform oncology and generous stock options. Production relies on its own base of unmodified T-cells. The ratio of cost to business expansion rates reflects the current market valuation, where the parameter has stabilized at 0.00.

When screening for reliable issuers, investors utilize the PEG ratio to compare market value with earnings growth. This metric is calculated by dividing the P/E ratio by the expected growth rate of net income. For Marker Therapeutics (MRKR), this calculation reflects the monetization potential of MultiTAA therapy through insurance reimbursements. A value below one indicates that the asset is undervalued. By analyzing the average PEG value, investors can identify promising entry points.